On December 7, the concept stock of ursodeoxycholic acid broke out across the board, with Sinotherapeutics and Gonggong Pharmaceutical gaining a 20CM price limit, and Shuangcheng Pharmaceutical and Qianhong Pharmaceutical gaining a limit
.
At the same time, the attention to ursodeoxycholic acid on the investor interactive platform has also soared, and a number of listed companies have been asked about ursodeoxycholic acid-related business
.
In this regard, Xinhua Pharmaceutical issued a change announcement saying that Shandong Zibo Xinda Pharmaceutical Co.
, Ltd.
, a wholly-owned subsidiary of the company, obtained the qualification of marketing authorization holder of ursodeoxycholic acid tablets in June 2022, and the clinical indication is for the treatment of cholesterol-type gallstones, but it has not yet been commercially produced
.
Xinhua Pharmaceutical said in the announcement that the company's A-share stocks on December 5, December 6 and December 7, 2022, the closing price increase deviation of three consecutive trading days accumulated more than 20%, which is an abnormal
fluctuation of stock trading 。 Xinhua Pharmaceutical said that although the Group has obtained the necessary approvals from the National Medical Products Administration of China to sell drugs for the treatment of cholesterol-type gallstones ursodeoxycholic acid in the Chinese market since June 2022, the Company would like to clarify that the article or related research related to the article is not commissioned by the Group; The Group has not commercialized or sold any ursodeoxycholic acid drugs to date; and the clinical indication of the ursodeoxycholic acid drug to be produced by the Group is the treatment of cholesterol-type gallstones
.
Saisheng Pharmaceutical said on the investor interactive platform on December 7 that its subsidiary Junyuan Pharmaceutical has ursodeoxycholic acid tablet products and has the production conditions
for related dosage forms.
Tonghua Jinma said on the interactive platform on December 7 that the company's subsidiary, Chengdu Yongkang Pharmaceutical Co.
, Ltd.
, is engaged in black bear breeding business, and has a bear bile powder registration number and products
.
Gibel said on the investor interactive platform that it has the drug registration approval for ursodeoxycholic acid tablets (approval number: Sinopharm H32024896; Specification: 50mg), relying on the deuterated drug research and development technology platform, is carrying out the research and development
of raw materials and preparations of a new generation of gallstone treatment drug JJH201801.
Sinotherapeutics also recently said on the investor interactive platform that ursodeoxycholic acid capsule products will be commercially supplied
in the near future.
In October this year, Guangshengtang issued an announcement that it planned to sign a "technology transfer contract" with Ruitai Lai, and Ruitai transferred all the technology and corresponding data and all rights and interests and corresponding technical data of the ursodeoxycholic acid capsule preparation (specification: 250mg) owned by Ruitai to the company, with a transaction amount of 13.
5 million yuan
.
Guangshengtang said that ursodeoxycholic acid capsules play a role in protecting liver cell membranes and choleretic effects, which can be used to treat drug-induced liver injury and cholestatic liver disease, and the signing of the "Technology Transfer Contract" is conducive to expanding the company's product series in the field of liver protection and liver protection, and further enriching the company's product pipeline
.
Mutual Pharmaceutical said that the company is currently independently developing a production process for the production of ursodeoxycholic acid using didownol as raw material, and has opened up the process route
.
At the same time, the company has established business cooperation with ICE GROUP, a major ursodeoxycholic acid manufacturer in the world, and realized the sales of ursodeoxycholic acid intermediate products
to it.
The follow-up company will strive to become the core supplier of the company's plant-derived ursodeoxycholic acid, or cooperate with it in a project to jointly develop and produce plant-derived ursodeoxycholic acid
.
It is reported that Commonshare Pharmaceutical said in the offering memorandum of convertible corporate bonds that the investment product didownol has broad application space in the downstream progesterone, ursodeoxycholic acid, plant-derived cholesterol and vitamin D3 markets, of which the demand for bis-hypophenol corresponding to the ursodeoxycholic acid market is about 1700 tons / year
.
On the whole, the downstream market demand space of the company's fundraising and investment products is large, and it will continue to show a growth trend
.
In addition, Haichen Pharmaceutical obtained the production license of ursodeoxycholic acid in 2022; The generic drug R&D project owned by Fuyuan Pharmaceutical contains ursodeoxycholic acid capsules; The research and development plan of the group includes taursodeoxycholic acid capsules; CR Shuanghe's ursodeoxycholic acid tablets have obtained production approval; The main product of the local pharmaceutical company in the United States acquired by Humanwell contains ursodeoxycholic acid capsules.
.
.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
